Literature DB >> 18511248

Evaluation of injection moulding as a pharmaceutical technology to produce matrix tablets.

Thomas Quinten1, Thomas De Beer, Chris Vervaet, Jean Paul Remon.   

Abstract

The aim of this study was to develop sustained-release matrix tablets by means of injection moulding and to evaluate the influence of process temperature, matrix composition (EC and HPMC concentration) and viscosity grade of ethylcellulose (EC) and hydroxypropylmethylcellulose (HPMC) on processability and drug release. The drug release data were analyzed to get insight in the release kinetics and mechanism. Formulations containing metoprolol tartrate (30%, model drug), EC with dibutyl sebacate (matrix former and plasticizer) and hydrophilic polymer HPMC were extruded and subsequently injection moulded into tablets (375 mg, 10 mm diameter, convex-shaped) at temperatures ranging from 110 to 140 degrees C. Tablets containing 30% metoprolol and 70% ethylcellulose (EC 4mPa s) showed an incomplete drug release within 24 h (<50%). Increasing production temperatures resulted in a lower drug release rate. Substituting part of the EC fraction by HPMC (HPMC/EC-ratio: 20/50 and 35/35) resulted in faster and constant drug release rates. Formulations containing 50% HPMC had a complete and first-order drug release profile with drug release controlled via the combination of diffusion and swelling/erosion. Faster drug release rates were observed for higher viscosity grades of EC (Mw>20 mPa s) and HPMC (4000 and 10,000 mPa s). Tablet porosity was low (<4%). Differential scanning calorimetry (DSC) and X-ray powder diffraction studies (X-RD) showed that solid dispersions were formed during processing. Using thermogravimetrical analysis (TGA) and gel-permeation chromatography no degradation of drug and matrix polymer was observed. The surface morphology was investigated with the aid of scanning electron microscopy (SEM) showing an influence of the process temperature. Raman spectroscopy demonstrated that the drug is distributed in the entire matrix, however, some drug clusters were identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18511248     DOI: 10.1016/j.ejpb.2008.02.025

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Miniaturization in pharmaceutical extrusion technology: feeding as a challenge of downscaling.

Authors:  Christian Muehlenfeld; Markus Thommes
Journal:  AAPS PharmSciTech       Date:  2011-12-09       Impact factor: 3.246

2.  Preparation and evaluation of sustained-release matrix tablets based on metoprolol and an acrylic carrier using injection moulding.

Authors:  T Quinten; G P Andrews; T De Beer; L Saerens; W Bouquet; D S Jones; P Hornsby; J P Remon; C Vervaet
Journal:  AAPS PharmSciTech       Date:  2012-09-11       Impact factor: 3.246

3.  Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies.

Authors:  Shufang Nie; W L Wendy Hsiao; Weisan Pan; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2011-01-19

Review 4.  Solvent-free melting techniques for the preparation of lipid-based solid oral formulations.

Authors:  Karin Becker; Sharareh Salar-Behzadi; Andreas Zimmer
Journal:  Pharm Res       Date:  2015-03-19       Impact factor: 4.200

Review 5.  Continuous Formulation Approaches of Amorphous Solid Dispersions: Significance of Powder Flow Properties and Feeding Performance.

Authors:  Edina Szabó; Balázs Démuth; Dorián László Galata; Panna Vass; Edit Hirsch; István Csontos; György Marosi; Zsombor K Nagy
Journal:  Pharmaceutics       Date:  2019-12-05       Impact factor: 6.321

6.  Single and dual drug release patterns from shellac wax-lutrol matrix tablets fabricated with fusion and molding techniques.

Authors:  T Phaechamud; C Choncheewa
Journal:  Indian J Pharm Sci       Date:  2015 Jan-Feb       Impact factor: 0.975

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.